Does the media prefer REGN or UTHR?

In the previous week, Regeneron Pharmaceuticals had 23 more articles in the media than United Therapeutics. MarketBeat recorded 45 mentions for Regeneron Pharmaceuticals and 22 mentions for United Therapeutics. Regeneron Pharmaceuticals' average media sentiment score of 1.18 beat United Therapeutics' score of 0.82 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 33 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Positive United Therapeutics 14 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALNY or UTHR?

In the previous week, United Therapeutics had 1 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 22 mentions for United Therapeutics and 21 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.23 beat United Therapeutics' score of 0.82 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 13 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive United Therapeutics 14 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer UTHR or BIIB?

In the previous week, Biogen had 5 more articles in the media than United Therapeutics. MarketBeat recorded 27 mentions for Biogen and 22 mentions for United Therapeutics. Biogen's average media sentiment score of 0.94 beat United Therapeutics' score of 0.82 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 14 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 12 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer INCY or UTHR?

In the previous week, Incyte had 16 more articles in the media than United Therapeutics. MarketBeat recorded 38 mentions for Incyte and 22 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.82 beat Incyte's score of 0.59 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 16 Very Positive mention(s) 1 Positive mention(s) 13 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Positive United Therapeutics 14 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor UTHR or NBIX?

In the previous week, United Therapeutics had 9 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 22 mentions for United Therapeutics and 13 mentions for Neurocrine Biosciences. United Therapeutics' average media sentiment score of 0.82 beat Neurocrine Biosciences' score of 0.64 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 14 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

United Therapeutics (UTHR) Competitors

$545.96 +0.56 (+0.10%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$543.46 -2.50 (-0.46%)

As of 06/12/2026 07:58 PM Eastern

Compare

UTHR vs. REGN, ALNY, BIIB, INCY, and NBIX

Should you buy United Therapeutics stock or one of its competitors? MarketBeat compares United Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with United Therapeutics include Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry.

How does United Therapeutics compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

United Therapeutics has a net margin of 40.62% compared to Regeneron Pharmaceuticals' net margin of 29.65%. United Therapeutics' return on equity of 19.24% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
United Therapeutics	40.62%	19.24%	17.25%

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Regeneron Pharmaceuticals has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

Regeneron Pharmaceuticals has higher revenue and earnings than United Therapeutics. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	4.51	$4.50B	$41.04	14.92
United Therapeutics	$3.17B	7.31	$1.33B	$27.09	20.15

In the previous week, Regeneron Pharmaceuticals had 23 more articles in the media than United Therapeutics. MarketBeat recorded 45 mentions for Regeneron Pharmaceuticals and 22 mentions for United Therapeutics. Regeneron Pharmaceuticals' average media sentiment score of 1.18 beat United Therapeutics' score of 0.82 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	33 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Positive
United Therapeutics	14 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals presently has a consensus target price of $792.65, suggesting a potential upside of 29.49%. United Therapeutics has a consensus target price of $619.42, suggesting a potential upside of 13.45%. Given Regeneron Pharmaceuticals' higher possible upside, equities analysts plainly believe Regeneron Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.70
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

United Therapeutics beats Regeneron Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does United Therapeutics compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Alnylam Pharmaceuticals currently has a consensus price target of $463.13, suggesting a potential upside of 63.74%. United Therapeutics has a consensus price target of $619.42, suggesting a potential upside of 13.45%. Given Alnylam Pharmaceuticals' higher probable upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 8.6% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

United Therapeutics has lower revenue, but higher earnings than Alnylam Pharmaceuticals. United Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	10.17	$313.75M	$3.66	77.28
United Therapeutics	$3.17B	7.31	$1.33B	$27.09	20.15

In the previous week, United Therapeutics had 1 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 22 mentions for United Therapeutics and 21 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.23 beat United Therapeutics' score of 0.82 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	13 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
United Therapeutics	14 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

United Therapeutics has a net margin of 40.62% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
United Therapeutics	40.62%	19.24%	17.25%

Summary

Alnylam Pharmaceuticals and United Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does United Therapeutics compare to Biogen?

United Therapeutics (NASDAQ:UTHR) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

United Therapeutics currently has a consensus target price of $619.42, indicating a potential upside of 13.45%. Biogen has a consensus target price of $217.26, indicating a potential upside of 8.60%. Given United Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe United Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Biogen	1 Sell rating(s)	12 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.55

United Therapeutics has higher earnings, but lower revenue than Biogen. United Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.17B	7.31	$1.33B	$27.09	20.15
Biogen	$9.89B	2.99	$1.29B	$9.32	21.46

In the previous week, Biogen had 5 more articles in the media than United Therapeutics. MarketBeat recorded 27 mentions for Biogen and 22 mentions for United Therapeutics. Biogen's average media sentiment score of 0.94 beat United Therapeutics' score of 0.82 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	14 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	12 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Biogen has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market.

United Therapeutics has a net margin of 40.62% compared to Biogen's net margin of 13.81%. United Therapeutics' return on equity of 19.24% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
Biogen	13.81%	12.83%	8.01%

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

United Therapeutics beats Biogen on 11 of the 17 factors compared between the two stocks.

How does United Therapeutics compare to Incyte?

Incyte (NASDAQ:INCY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

97.0% of Incyte shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 16.2% of Incyte shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Incyte had 16 more articles in the media than United Therapeutics. MarketBeat recorded 38 mentions for Incyte and 22 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.82 beat Incyte's score of 0.59 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	16 Very Positive mention(s)	1 Positive mention(s)	13 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Positive
United Therapeutics	14 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte currently has a consensus price target of $105.10, suggesting a potential downside of 3.16%. United Therapeutics has a consensus price target of $619.42, suggesting a potential upside of 13.45%. Given United Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe United Therapeutics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	13 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has lower revenue, but higher earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.36B	4.04	$1.29B	$7.08	15.33
United Therapeutics	$3.17B	7.31	$1.33B	$27.09	20.15

United Therapeutics has a net margin of 40.62% compared to Incyte's net margin of 26.71%. Incyte's return on equity of 26.66% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
United Therapeutics	40.62%	19.24%	17.25%

Incyte has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

Summary

United Therapeutics beats Incyte on 9 of the 16 factors compared between the two stocks.

How does United Therapeutics compare to Neurocrine Biosciences?

United Therapeutics (NASDAQ:UTHR) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

United Therapeutics currently has a consensus price target of $619.42, indicating a potential upside of 13.45%. Neurocrine Biosciences has a consensus price target of $187.52, indicating a potential upside of 17.38%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Neurocrine Biosciences is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.87

United Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

United Therapeutics has higher revenue and earnings than Neurocrine Biosciences. United Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.17B	7.31	$1.33B	$27.09	20.15
Neurocrine Biosciences	$2.86B	5.62	$478.60M	$6.49	24.62

United Therapeutics has a net margin of 40.62% compared to Neurocrine Biosciences' net margin of 21.55%. Neurocrine Biosciences' return on equity of 19.79% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
Neurocrine Biosciences	21.55%	19.79%	13.82%

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 8.6% of United Therapeutics shares are held by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, United Therapeutics had 9 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 22 mentions for United Therapeutics and 13 mentions for Neurocrine Biosciences. United Therapeutics' average media sentiment score of 0.82 beat Neurocrine Biosciences' score of 0.64 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	14 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

United Therapeutics beats Neurocrine Biosciences on 11 of the 17 factors compared between the two stocks.

Get United Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UTHR vs. The Competition

Export

Metric	United Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.17B	$2.98B	$6.72B	$12.07B
Dividend Yield	N/A	1.76%	2.67%	5.67%
P/E Ratio	20.15	18.84	24.24	24.42
Price / Sales	7.31	309.17	481.04	86.26
Price / Cash	16.55	56.48	43.54	55.64
Price / Book	3.31	3.99	10.65	6.80
Net Income	$1.33B	$75.85M	$3.57B	$338.00M
7 Day Performance	-0.71%	1.19%	0.84%	2.68%
1 Month Performance	-5.18%	-3.70%	-0.34%	1.56%
1 Year Performance	92.68%	23.44%	25.40%	30.59%

United Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UTHR United Therapeutics	4.1953 of 5 stars	$545.96 +0.1%	$619.42 +13.5%	+92.7%	$23.17B	$3.17B	20.15	1,400	Insider Trade
REGN Regeneron Pharmaceuticals	4.8575 of 5 stars	$611.34 -3.8%	$792.65 +29.7%	+15.7%	$67.18B	$14.34B	14.90	15,410	Positive News
ALNY Alnylam Pharmaceuticals	4.631 of 5 stars	$292.16 -3.6%	$463.13 +58.5%	-8.2%	$40.46B	$3.71B	79.83	2,770	News Coverage Positive News Analyst Upgrade
BIIB Biogen	3.5707 of 5 stars	$192.62 -1.4%	$217.26 +12.8%	+53.1%	$28.84B	$9.89B	20.67	7,500
INCY Incyte	2.827 of 5 stars	$100.64 -1.7%	$104.85 +4.2%	+60.2%	$20.45B	$5.14B	14.21	2,844	News Coverage Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UTHR) was last updated on 6/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

United Therapeutics (UTHR) Competitors

UTHR vs. REGN, ALNY, BIIB, INCY, and NBIX

How does United Therapeutics compare to Regeneron Pharmaceuticals?

Summary

How does United Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does United Therapeutics compare to Biogen?

Summary

How does United Therapeutics compare to Incyte?

Summary

How does United Therapeutics compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR vs. The Competition

United Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

United Therapeutics (UTHR) Competitors

UTHR vs. REGN, ALNY, BIIB, INCY, and NBIX

How does United Therapeutics compare to Regeneron Pharmaceuticals?

Is REGN or UTHR more profitable?

Do institutionals & insiders have more ownership in REGN or UTHR?

Which has more risk and volatility, REGN or UTHR?

Which has preferable valuation & earnings, REGN or UTHR?

Does the media prefer REGN or UTHR?

Do analysts prefer REGN or UTHR?

Summary

How does United Therapeutics compare to Alnylam Pharmaceuticals?

Do analysts prefer ALNY or UTHR?

Do insiders & institutionals have more ownership in ALNY or UTHR?

Which has stronger earnings and valuation, ALNY or UTHR?

Does the media prefer ALNY or UTHR?

Which has more risk & volatility, ALNY or UTHR?

Is ALNY or UTHR more profitable?

Summary

How does United Therapeutics compare to Biogen?

Do analysts prefer UTHR or BIIB?

Which has preferable valuation and earnings, UTHR or BIIB?

Does the media prefer UTHR or BIIB?

Which has more volatility and risk, UTHR or BIIB?

Is UTHR or BIIB more profitable?

Do insiders & institutionals hold more shares of UTHR or BIIB?

Summary

How does United Therapeutics compare to Incyte?

Do institutionals & insiders have more ownership in INCY or UTHR?

Does the media prefer INCY or UTHR?

Do analysts recommend INCY or UTHR?

Which has stronger earnings & valuation, INCY or UTHR?

Is INCY or UTHR more profitable?

Which has more volatility and risk, INCY or UTHR?

Summary

How does United Therapeutics compare to Neurocrine Biosciences?

Do analysts prefer UTHR or NBIX?

Which has more risk & volatility, UTHR or NBIX?

Which has stronger earnings and valuation, UTHR or NBIX?

Is UTHR or NBIX more profitable?

Do insiders & institutionals hold more shares of UTHR or NBIX?

Does the media favor UTHR or NBIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR vs. The Competition

United Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools